Hematologic Oncology | Specialty

Side Effect Management With Corticosteroids

October 27th 2013

The Role of Patient Education in Side Effect Management

October 27th 2013

Managing BRAF Inhibitor Associated Skin Toxicity

October 27th 2013

The Nurse's Role in Managing Skin Toxicity

October 27th 2013

Managing mTOR Inhibitor Induced Adverse Events

October 27th 2013

Interdisciplinary Approach to Managing Skin Toxicities

October 27th 2013

Managing Treatment-Related Hand-Foot Skin Reaction

October 27th 2013

Managing BCR-ABL Inhibitor Associated Skin Rash

October 27th 2013

Managing Angiogenesis Inhibitor Related Skin Toxicity

October 27th 2013

Anticipatory Coping in Patients Treated With EGFR Inhibitors

October 27th 2013

Managing EGFR Inhibitor Associated Skin Toxicity

October 27th 2013

Unique Considerations With TKIs for Chronic Myelogenous Leukemia

October 25th 2013

At the recent NCCN 8th Annual Congress on Hematologic Malignancies, Michael Millenson, MD, Fox Chase Cancer Center, discussed considerations in selecting second- and third-generation tyrosine-kinase inhibitors for the management of chronic myelogenous leukemia

Novel B-Cell Receptor Signaling Inhibitors Show Promise

October 23rd 2013

Drugs targeting B-cell receptor signaling pathways are improving outcomes for patients with B-cell lymphomas; these novel agents include idelalisib and ibrutinib, and are considered a breakthrough for CLL and other B-cell lymphomas.

Late-Stage Ponatinib Study Discontinued

October 18th 2013

The phase III EPIC trial that was exploring ponatinib in untreated patients with chronic myeloid leukemia has been discontinued following a high occurrence of arterial thrombotic events.

Positive Idelalisib Data Ends Late-Stage CLL Trial

October 10th 2013

A phase III study of the PI3K-delta inhibitor idelalisib in combination with rituximab has been stopped early following a positive interim analysis.

No Age Limit for Bone Marrow Transplantation

October 10th 2013

Age is no longer a consideration when determining whether an older patient with blood cancer is a candidate for stem cell transplantation.

Safety Concerns Halt Ponatinib Development

October 9th 2013

The FDA has placed a partial hold on the clinical development of the BCR-ABL inhibitor ponatinib, following the high occurrence of arterial thrombosis in patients treated with the drug.

National Cancer Institute Awards Leukemia Reseachers at Siteman $26 Million

October 7th 2013

The National Cancer Institute, part of the National Institutes of Health, has awarded two major grants totaling $26 million to leukemia researchers and physicians at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis.

It's All in the "Genes"

September 23rd 2013

I remember trying to explain to my son when he was in the fifth grade how the genetic code contained in all of our cells is translated, resulting in the various tissues we all possess for daily life

Dr. Woyach on the Role of BTK in CLL

September 20th 2013

Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the role of Bruton's tyrosine kinase (BTK) in chronic lymphocytic leukemia (CLL).